COO
The Cooper Companies, Inc. NASDAQ Listed Jan 21, 1983$61.10
Mkt Cap $11.9B
52w Low $60.00
3.7% of range
52w High $89.83
50d MA $71.04
200d MA $74.01
P/E (TTM)
33.2x
EV/EBITDA
15.8x
P/B
1.5x
Debt/Equity
0.3x
ROE
4.8%
P/FCF
32.2x
RSI (14)
—
ATR (14)
—
Beta
1.07
50d MA
$71.04
200d MA
$74.01
Avg Volume
2.0M
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
6101 Bollinger Canyon Road · San Ramon, CA 94583 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | AMC | 1.03 | 1.10 | +6.8% | 80.20 | -4.0% | -4.6% | -5.5% | -7.2% | -8.0% | -10.8% | — |
| Dec 4, 2025 | AMC | 1.11 | 1.15 | +3.6% | 77.03 | +16.4% | +5.7% | +1.3% | +1.9% | +4.8% | +6.6% | — |
| Aug 27, 2025 | AMC | 1.07 | 1.10 | +2.8% | 74.11 | -16.0% | -12.9% | -9.1% | -11.8% | -9.4% | -8.2% | — |
| May 29, 2025 | AMC | 0.93 | 0.96 | +3.4% | 79.96 | -10.0% | -14.6% | -16.2% | -16.3% | -15.7% | -11.0% | — |
| Mar 6, 2025 | AMC | 0.91 | 0.92 | +0.7% | 90.98 | -5.3% | -6.6% | -12.2% | -10.9% | -13.1% | -14.6% | — |
| Dec 5, 2024 | AMC | 1.00 | 1.04 | +4.0% | 103.23 | -3.7% | -4.4% | -3.8% | -4.0% | -3.8% | -6.3% | — |
| Aug 28, 2024 | AMC | 0.91 | 0.96 | +5.4% | 94.54 | +10.1% | +11.8% | +11.8% | +12.2% | +11.6% | +12.7% | — |
| May 30, 2024 | AMC | 0.83 | 0.85 | +2.5% | 90.23 | +6.4% | +4.5% | +5.0% | +4.8% | +4.4% | +5.6% | — |
| Feb 29, 2024 | AMC | 0.78 | 0.85 | +8.6% | 93.60 | +9.0% | +9.2% | +9.8% | +8.4% | +8.8% | +9.1% | — |
| Dec 7, 2023 | AMC | 0.87 | 0.87 | +0.0% | 86.24 | -0.3% | -2.9% | -1.6% | -1.4% | +3.1% | +6.5% | — |
| Aug 30, 2023 | AMC | 0.84 | 0.84 | +0.0% | 95.21 | -0.7% | -2.8% | -4.2% | -7.5% | -6.4% | -7.1% | — |
| Jun 1, 2023 | AMC | 0.75 | 0.77 | +2.7% | 93.55 | -3.8% | -4.7% | -5.5% | -5.8% | -6.3% | -6.5% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 6 | Citigroup | Maintains | Neutral → Neutral | — | $80.20 | $77.00 | -4.0% | -4.6% | -5.5% | -7.2% | -8.0% | -10.8% |
| Mar 6 | Needham | Maintains | Buy → Buy | — | $80.20 | $77.00 | -4.0% | -4.6% | -5.5% | -7.2% | -8.0% | -10.8% |
| Mar 6 | Barclays | Maintains | Overweight → Overweight | — | $80.20 | $77.00 | -4.0% | -4.6% | -5.5% | -7.2% | -8.0% | -10.8% |
| Feb 3 | Needham | Maintains | Buy → Buy | — | $80.65 | $80.39 | -0.3% | -1.6% | +0.3% | -0.7% | +1.8% | +1.0% |
| Jan 26 | Barclays | Maintains | Overweight → Overweight | — | $81.29 | $81.52 | +0.3% | -0.5% | -0.7% | -1.0% | -1.1% | +0.1% |
| Dec 8 | Citigroup | Maintains | Neutral → Neutral | — | $81.40 | $81.70 | +0.4% | -4.1% | -3.6% | -0.8% | +0.9% | +0.8% |
| Dec 8 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $81.40 | $81.70 | +0.4% | -4.1% | -3.6% | -0.8% | +0.9% | +0.8% |
| Dec 8 | Goldman Sachs | Maintains | Sell → Sell | — | $81.40 | $81.70 | +0.4% | -4.1% | -3.6% | -0.8% | +0.9% | +0.8% |
| Dec 5 | JP Morgan | Maintains | Neutral → Neutral | — | $77.03 | $89.66 | +16.4% | +5.7% | +1.3% | +1.9% | +4.8% | +6.6% |
| Dec 5 | Mizuho | Maintains | Outperform → Outperform | — | $77.03 | $89.66 | +16.4% | +5.7% | +1.3% | +1.9% | +4.8% | +6.6% |
| Dec 5 | Piper Sandler | Maintains | Overweight → Overweight | — | $77.03 | $89.66 | +16.4% | +5.7% | +1.3% | +1.9% | +4.8% | +6.6% |
| Dec 5 | Baird | Maintains | Outperform → Outperform | — | $77.03 | $89.66 | +16.4% | +5.7% | +1.3% | +1.9% | +4.8% | +6.6% |
| Dec 5 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $77.03 | $89.66 | +16.4% | +5.7% | +1.3% | +1.9% | +4.8% | +6.6% |
| Dec 5 | Needham | Maintains | Buy → Buy | — | $77.03 | $89.66 | +16.4% | +5.7% | +1.3% | +1.9% | +4.8% | +6.6% |
| Dec 5 | Stifel | Maintains | Buy → Buy | — | $77.03 | $89.66 | +16.4% | +5.7% | +1.3% | +1.9% | +4.8% | +6.6% |
| Nov 13 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $72.49 | $71.43 | -1.5% | -1.0% | -0.5% | -1.6% | -0.4% | -0.5% |
| Aug 28 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $74.11 | $62.27 | -16.0% | -12.9% | -9.1% | -11.8% | -9.4% | -8.2% |
| Aug 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $74.11 | $62.27 | -16.0% | -12.9% | -9.1% | -11.8% | -9.4% | -8.2% |
| Aug 28 | Citigroup | Downgrade | Buy → Neutral | — | $74.11 | $62.27 | -16.0% | -12.9% | -9.1% | -11.8% | -9.4% | -8.2% |
| Aug 28 | Stifel | Maintains | Buy → Buy | — | $74.11 | $62.27 | -16.0% | -12.9% | -9.1% | -11.8% | -9.4% | -8.2% |
| Aug 28 | Needham | Maintains | Buy → Buy | — | $74.11 | $62.27 | -16.0% | -12.9% | -9.1% | -11.8% | -9.4% | -8.2% |
| Aug 28 | Piper Sandler | Maintains | Overweight → Overweight | — | $74.11 | $62.27 | -16.0% | -12.9% | -9.1% | -11.8% | -9.4% | -8.2% |
| Aug 28 | JP Morgan | Maintains | Neutral → Neutral | — | $74.11 | $62.27 | -16.0% | -12.9% | -9.1% | -11.8% | -9.4% | -8.2% |
| Aug 28 | Baird | Maintains | Outperform → Outperform | — | $74.11 | $62.27 | -16.0% | -12.9% | -9.1% | -11.8% | -9.4% | -8.2% |
| Jul 16 | Mizuho | Maintains | Outperform → Outperform | — | $72.20 | $73.10 | +1.2% | +0.7% | +1.5% | +0.6% | -1.2% | +1.1% |
| Jun 17 | Needham | Upgrade | Hold → Buy | — | $69.74 | $70.34 | +0.9% | -1.4% | +0.1% | -0.4% | -0.3% | +1.7% |
| May 30 | Baird | Maintains | Outperform → Outperform | — | $79.96 | $71.98 | -10.0% | -14.6% | -16.2% | -16.3% | -15.7% | -11.0% |
| May 30 | Wells Fargo | Maintains | Overweight → Overweight | — | $79.96 | $71.98 | -10.0% | -14.6% | -16.2% | -16.3% | -15.7% | -11.0% |
| May 30 | Piper Sandler | Maintains | Overweight → Overweight | — | $79.96 | $71.98 | -10.0% | -14.6% | -16.2% | -16.3% | -15.7% | -11.0% |
| May 30 | Needham | Maintains | Hold → Hold | — | $79.96 | $71.98 | -10.0% | -14.6% | -16.2% | -16.3% | -15.7% | -11.0% |
| May 30 | JP Morgan | Downgrade | Overweight → Neutral | — | $79.96 | $71.98 | -10.0% | -14.6% | -16.2% | -16.3% | -15.7% | -11.0% |
| May 22 | Needham | Maintains | Hold → Hold | — | $79.37 | $79.37 | +0.0% | -0.1% | -0.7% | +1.5% | +0.9% | +0.7% |
| Mar 7 | Baird | Maintains | Outperform → Outperform | — | $90.98 | $86.18 | -5.3% | -6.6% | -12.2% | -10.9% | -13.1% | -14.6% |
| Mar 7 | Stifel | Maintains | Buy → Buy | — | $90.98 | $86.18 | -5.3% | -6.6% | -12.2% | -10.9% | -13.1% | -14.6% |
| Mar 7 | Citigroup | Maintains | Buy → Buy | — | $90.98 | $86.18 | -5.3% | -6.6% | -12.2% | -10.9% | -13.1% | -14.6% |
| Mar 7 | JP Morgan | Maintains | Overweight → Overweight | — | $90.98 | $86.18 | -5.3% | -6.6% | -12.2% | -10.9% | -13.1% | -14.6% |
| Mar 7 | Needham | Maintains | Hold → Hold | — | $90.98 | $86.18 | -5.3% | -6.6% | -12.2% | -10.9% | -13.1% | -14.6% |
| Mar 7 | Piper Sandler | Maintains | Overweight → Overweight | — | $90.98 | $86.18 | -5.3% | -6.6% | -12.2% | -10.9% | -13.1% | -14.6% |
| Dec 6 | Needham | Maintains | Hold → Hold | — | $103.23 | $99.39 | -3.7% | -4.4% | -3.8% | -4.0% | -3.8% | -6.3% |
| Dec 6 | Citigroup | Maintains | Buy → Buy | — | $103.23 | $99.39 | -3.7% | -4.4% | -3.8% | -4.0% | -3.8% | -6.3% |
| Dec 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $103.23 | $99.39 | -3.7% | -4.4% | -3.8% | -4.0% | -3.8% | -6.3% |
| Dec 6 | Wells Fargo | Maintains | Overweight → Overweight | — | $103.23 | $99.39 | -3.7% | -4.4% | -3.8% | -4.0% | -3.8% | -6.3% |
| Mar 13 | JP Morgan | Upgrade | Neutral → Overweight | — | $101.54 | $103.50 | +1.9% | +0.8% | -0.0% | -0.8% | -0.7% | +0.7% |
| Mar 1 | JP Morgan | Maintains | Neutral → Neutral | — | $93.60 | $102.04 | +9.0% | +9.2% | +9.8% | +8.4% | +8.8% | +9.1% |
| Mar 1 | Mizuho | Maintains | Buy → Buy | — | $93.60 | $102.04 | +9.0% | +9.2% | +9.8% | +8.4% | +8.8% | +9.1% |
| Mar 1 | Stifel | Maintains | Buy → Buy | — | $93.60 | $102.04 | +9.0% | +9.2% | +9.8% | +8.4% | +8.8% | +9.1% |
| Mar 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $93.60 | $102.04 | +9.0% | +9.2% | +9.8% | +8.4% | +8.8% | +9.1% |
| Jan 12 | Piper Sandler | Maintains | Overweight → Overweight | — | $95.13 | $96.08 | +1.0% | +0.9% | +0.6% | -0.5% | +1.4% | +1.8% |
| Dec 4 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $85.27 | $84.61 | -0.8% | -0.8% | -1.7% | +0.4% | +1.1% | -1.8% |
| Nov 29 | JP Morgan | Maintains | Neutral → Neutral | — | $83.58 | $83.74 | +0.2% | -0.8% | +0.8% | +2.0% | +1.2% | +0.3% |
No insider trades available.
8-K · 5.02
!!! Very High
The Cooper Companies, Inc. -- 8-K 5.02: Executive Change
Cooper Companies appointed Paul Keel as an independent director, strengthening board governance and oversight of the medical device company's operations.
May 4
8-K
Unknown — 8-K Filing
I cannot provide a meaningful analysis because the filing summary provided is incomplete and contains only technical metadata rather than substantive business information about Cooper-Standard Holdings or the actual 8-K content.
Apr 8
8-K
The Cooper Companies, Inc. -- 8-K Filing
Cooper Companies reported Q1 2026 revenue of $1.024 billion, up 6% year-over-year (3% organic growth), demonstrating modest but steady expansion in its medical device business.
Mar 5
8-K
The Cooper Companies, Inc. -- 8-K Filing
Cooper Companies amended its 2024 Credit Agreement to align provisions with its 2021 Loan Agreement and eliminate credit spread adjustments, streamlining its debt structure.
Feb 4
Data updated apr 25, 2026 2:38am
· Source: massive.com